A5081376530- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- RNA Interference and Gene Delivery
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Endometriosis Research and Treatment
- PI3K/AKT/mTOR signaling in cancer
Dana-Farber Cancer Institute
2015-2025
Dana-Farber Brigham Cancer Center
2016-2025
Harvard University
2014-2025
Takeda (United States)
2025
Sanofi (United States)
2020-2023
Beth Israel Deaconess Medical Center
2011-2023
Brigham and Women's Hospital
2016
Friedrich-Alexander-Universität Erlangen-Nürnberg
2005-2015
Duke Cancer Institute
2011
Duke Medical Center
2008-2011
During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial (MET) as part of a broad invasion metastasis program. We previously observed MET events among lung metastases in preclinical model prostate adenocarcinoma that suggested relationship between epithelial plasticity metastatic spread. thus sought to translate these findings into clinical evidence by examining the existence EMT circulating tumor (CTC) from patients with...
BACKGROUND Next‐generation sequencing (NGS) allows for simultaneous of multiple cancer susceptibility genes and, an individual, may be more efficient and less expensive than sequential testing. The authors assessed the frequency deleterious germline mutations among individuals with breast who were referred BRCA1 BRCA2 ( BRCA1/2 ) gene testing using a panel 25 associated inherited predisposition. METHODS This was cross‐sectional study NGS in 2158 individuals, including 1781 commercial (cohort...
<h3>Importance</h3> To date, single-agent programmed cell death 1 protein (PD-1)/programmed ligand (PD-L1) immune checkpoint blockade has shown limited activity in recurrent epithelial ovarian cancer. Combination strategies of PD-1/PD-L1 inhibition with antiangiogenic therapy have the potential for synergistic through modulation microenvironment and represent a therapeutic opportunity this disease. <h3>Objective</h3> evaluate combined nivolumab bevacizumab women relapsed <h3>Design, Setting,...
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity HER2-positive cancer; however, its unknown. We evaluated efficacy treatment neratinib patients brain metastases a multicenter, phase II open-label trial.Eligible were those (≥ 1 cm longest dimension) who experienced progression after one or more line CNS-directed...
Background Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC) or advanced ovarian (AOC). The combination was also evaluated fulvestrant MBC. Methods In Cohort A, administered on Days 1–21 (28-day cycle) starting at 400 mg, mg Day 1. Dose escalation...
Abstract Purpose: A phase II study of dasatinib, an inhibitor multiple oncogenic tyrosine kinases including Src, was conducted to evaluate 16-week progression-free rate and tolerability in patients with previously treated metastatic breast cancer (MBC). Real-time assessment potential tissue biomarkers Src inhibition used optimize dosing. Experimental Design: Eligibility criteria required that have measurable MBC, biopsiable tumor, unlimited prior therapies. For the analysis change protein...
528 Background: Amcenestrant is an optimized oral selective ER degrader (SERD) that antagonizes and degrades the has demonstrated favorable preliminary safety antitumor activity as monotherapy in combination with palbociclib postmenopausal patients ER+/HER2− advanced breast cancer, irrespective of baseline (BL) ESR1 mutation status. Here we present final results AMEERA-4 (NCT04191382), a Phase 2 preoperative WOO study evaluated PD two dose levels amcenestrant or letrozole using paired...
Abstract Background Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experience side effects and reduced quality of life (QoL) discontinue ET. We sought to describe these issues develop a prediction model early discontinuation Methods Among with hormone receptor–positive HER2-negative stage I-III the Cancer Toxicities cohort (NCT01993498) who were prescribed ET between 2012 2017, upon stratification by menopausal status, we evaluated patterns including treatment...
TPS607 Background: There are currently limited treatment options for patients with HR+ EBC who have discontinued adjuvant aromatase inhibitors (AIs) due to treatment-related toxicity. Amcenestrant is an optimized oral selective estrogen receptor degrader (SERD) potent dual activity which antagonizes and degrades the ER resulting in inhibition of signalling pathway. Preliminary clinical evidence from phase 1/2 AMEERA-1 trial has demonstrated meaningful antitumour a favourable safety profile...
Abstract Background: About 30% of patients (pts) with hormone receptor (HR)-positive early breast cancer (EBC) on adjuvant aromatase inhibitor (AI) therapy discontinue due to toxicity 22% pts discontinuing during the first year (Henry et al. JCO 2012). For these who struggle AIs, there are limited alternatives including switch a different AI which may have similar side effects, tamoxifen, or observation. This paucity effective and tolerable options contribute poor adherence and/or...
Abstract Background: Immune checkpoint inhibitors (ICI), such as those targeting the PD-1/PD-L1 axis, have shown modest activity monotherapy in both HR+ MBC and MOC. Strategies to improve ICI for these diseases are under investigation. In mouse models, CDK4/6 boost anti-tumor immunity part by increasing infiltration activation of cytotoxic T lymphocytes, suppressing regulatory lymphocyte function, providing rationale combining inhibition ICI. Methods: We conducted an open-label phase 1b dose...
Window-of-opportunity (WOO) studies provide insights into the clinical activity of new drugs in breast cancer.AMEERA-4 (NCT04191382) was a WOO study undertaken to compare pharmacodynamic effects amcenestrant, selective estrogen receptor degrader, with those letrozole postmenopausal women newly diagnosed, operable receptor-positive, human epidermal growth factor 2-negative (ER+/HER2-) cancer. Women were randomized (1:1:1) receive amcenestrant 400 mg, 200 or 2.5 mg once daily for 14 days...
TPS1108 Background: Endocrine therapy targeting ER signaling is the standard of care for women with ER+ breast cancer. Selective degraders (SERDs) block through dual competitive antagonism and receptor degradation. SAR439859, a potent, oral SERD, in clinical development ER+/HER2- This study 14-day preoperative non-therapeutic ‘window opportunity’ trial to assess direct effects SAR439859 on tumor cell proliferation by evaluating pharmacodynamic activity Methods: international, open-label,...
Primary systemic therapy (PST) is a common treatment strategy used to optimize surgical outcomes for women with locally advanced breast cancer. Several cooperative group trials have shown equivalent survival between neoadjuvant and adjuvant chemotherapy identified pathologic complete response (pCR) as biologic marker survival. Research efforts PST include the development of strategies predict individual guide choice chemotherapy. These emerging approaches are informed by our knowledge...
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities lenalidomide, dose-limiting myelosuppression, are well described. However, the properties lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe case immune thrombocytopenic purpura (ITP) associated with use lenalidomide.
e12509 Background: Extended (≥5-year) adjuvant endocrine therapy (ET) is generally the preferred treatment approach for patients with hormone receptor–positive (HR+) breast cancer at high risk of recurrence. However, due to side effect burden and other challenges, patient adherence extended ET often suboptimal, presenting challenges healthcare providers alike. To further understand potential barriers adherence, objective this study was explore effects impacts among women HR+ through in-depth...
Abstract Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy. Selective receptor degraders (SERDs), such as fulvestrant, induce effective ER signaling inhibition, although clinical studies with fulvestrant report insufficient blockade of signaling, possibly due to suboptimal pharmaceutical properties. Here we describe the discovery SAR439859 (Amcenestrant), a novel, orally bioavailable SERD potent antagonist and degradation activities against both...
307 Background: Efficient use of exam rooms is crucial to be able accommodate increasing patient volumes. One workflow approach that takes patients into an room only when the provider ready can free up space for other patient-provider pairs (co-rooming), in contrast rooming before knowing provider’s readiness status (sequential-rooming). We conducted a pilot implement co-rooming on breast cancer floor at Dana-Farber Cancer Institute (DFCI) and assess whether time alone reduced. Methods: As...